Not Just for Diabetes: The Next Frontier for GLP-1 Agonists.

A commonly used GLP-1 agonist, semaglutide, reduces the risk of adverse cardiovascular outcomes in non-diabetic individuals with obesity and pre-existing cardiovascular disease.